N. Patel

Evaluation of the Abbott Architect, Roche Elecsys and Virtus S1 SARS-CoV-2 antibody tests in community-managed COVID-19 cases

S. Johnston, P. McKay, R. Shattock, 2020, medRxiv.

Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein

Antonio Polley, M. Morin, M. Robinson, 2021, bioRxiv.

IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2

M. Diamond, Antonio Polley, M. Morin, 2022, Science Immunology.

Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody Cocktail

M. Diamond, Antonio Polley, M. Morin, 2021, bioRxiv.

Clinicogenomic analysis of breakthrough infections by SARS CoV2 variants after ChAdOx1 nCoV- 19 vaccination in healthcare workers

S. Sarin, A. Agrawal, M. Faruq, 2021, medRxiv.

IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation

M. Morin, J. P. Finn, M. Robinson, 2023, mAbs.